Patent classifications
C12N2509/10
NANO-ENGINEERED THERAPEUTIC STEALTH CELLS
Disclosed herein is a method of “reprogramming” highly motile cells found in tumors, such as these highly motile GSC and/or MDSC clones, into “auto-destructive” cell “missiles” (referred to herein as therapeutic stealth cells) that can seek and destroy new foci of recurrence within the body, such as the brain. Cells with enhanced motility can be sorted out from heterogeneous populations and then be rendered “auto-destructive” by deterministic delivery of an anti-cancer agent, such as an oncolytic virus plasmid cocktail.
Single cells pluripotent stem cells in a suspension culture
Provided is an isolated population of human pluripotent stem cells comprising at least 50% human pluripotent stem cells characterized by an OCT4+/TRA1-60−/TRA1-81−/SSEA1+/SSEA4− expression signature, and novel methods of generating and maintaining same in a pluripotent, undifferentiated state a suspension culture devoid of cell clumps. Also provided are novel culture media, cell cultures and methods for culturing pluripotent stem cells in a suspension culture or a two-dimensional culture system while maintaining the cells in a proliferative, pluripotent and undifferentiated state. The novel culture media comprise interleukin 11 (IL11) and Ciliary Neurotrophic Factor (CNTF); bFGF at a concentration of at least 50 ng/ml and an IL6RIL6 chimera; or an animal contaminant-free serum replacement and an IL6RIL6 chimera. Also provided are methods for generating lineage-specific cells from the pluripotent stem cells.
METHODS OF PREPARING AND USING NOVEL STEM CELL COMPOSITIONS AND KITS COMPRISING THE SAME
The present invention provides novel stem cell compositions having significant therapeutic and practical advantages, as well as methods of preparing and using such compositions for the treatment and prevention of injury and disease in patients. The invention may be applied to stem cell populations isolated from a wide variety of animals, including humans, and tissues. In particular applications, the invention is used to prepare a stem cell composition from a collagen-based tissue, such as adipose tissue, isolated from a patient, and the stem cell composition is subsequently provided to a site of actual or potential injury in the patient. The invention further includes related kits comprising the stem cell compositions, which are remarkably stable and retain viability and efficacy during storage and shipment.
CELL MANIPULATION DEVICE AND CELL MANIPULATION METHOD
A cell manipulation method is provided including culturing cells in a liquid; disposing a flow path through which a gas is able to be introduced in the liquid; forming an air bubble at an end portion of the flow path; and attaching the cells to the air bubble.
TUMOR ORGANOID CULTURE COMPOSITIONS, SYSTEMS, AND METHODS
Provided herein are novel organoid culture media, organoid culture systems, and methods of culturing tumor organoids using the subject organoid culture media. Also provided herein are tumor organoids developed using such organoid culture systems, methods for assessing the clonal diversity of the tumor organoids, and methods for using such tumor organoids, for example, for tumor modelling and drug development applications. In particular embodiments, the tumor organoid culture media provided herein is substantially free of R-spondins (e.g., R-spondin1).
METHOD FOR ISOLATING AND MASS PROLIFERATING DERMAL PAPILLA CELLS DERIVED FROM SCALP TISSUE
Provided is a method for isolation and expansion of dermal papilla cells, and more particularly, to a method of isolating dermal papilla cells from hair bulbs, isolated from scalp tissue, by chopping, and then expanding the isolated dermal papilla cells by passaging. The expanded dermal papilla cells may play an important role in hair growth, and thus the present invention may be used in various industrial fields, including the medical field and the cosmetic field.
METHOD AND APPARATUS FOR IMPROVED MESENCHYMAL STEM CELL HARVESTING
A mesenchymal stem cell harvesting system and method for increasing the efficiency of collecting and processing physiological fluids containing mesenchymal stem cells from a cavity within a patient's skeletal system. Microenvironments risk in MSC production and concentration within a cavity, for example the patient's ilium, are penetrated with a pointed instrument used to create an aperture in the hard cortical bone forming the cavity followed by the insertion of an aspiration device which extracts one or more samples of cancellous bone, bone marrow, bone marrow blood and other aspirated material. The aspirate is rinsed and may be filtered to remove unwanted material and to increase the concentration and purity of the mesenchymal stem cells in the aspirant far beyond levels formerly obtainable for use in autologous treatment of the patient.
METHOD FOR DECELLULARIZATION OF SKIN TISSUE, METHOD FOR CONSTRUCTION OF ARTIFICIAL SKIN, METHOD FOR PREPARATION OF HYDROGEL OF DECELLULARIZED SKIN TISSUE, LYOPHILIZED, DECELLULARIZED SKIN TISSUE, AND BIOINK
A method for decellularization of a skin tissue according to an embodiment of the present invention comprises: a step of preparing a skin tissue to be decellularized; a peeling preparation step of treating the skin tissue with a first solution containing trypsin; and a peeling step of removing subcutaneous fat from the skin tissue after the peeling preparation step.
Stem cells and decellularization of tissue matrix from cord tissue
Methods and products obtained from the method for isolating and culturing mixed populations of stem cells, making decellularized tissue matrix, making decellularized tissue matrix infused with said mixed populations of stem cells, and methods of stem cell therapy are provided.
DEVICES, METHODS, AND KITS FOR PREPARING A CELL SUSPENSION
In some embodiments, a kit for preparing a cell suspension may include a device and a housing. The device may include a first label identifying a first reservoir of the device for use with a first portion of a tissue processing method and a second label identifying a second reservoir of the device for use with a second portion of the tissue processing method. The housing includes a first housing portion configured to store a first set of components associated with the first portion of the tissue processing method. The first housing portion includes a first visual indicator associated with the first label of the device. The second housing portion may be configured to store a second set of components associated with the second portion of the tissue processing method. The second housing portion may include a second visual indicator associated with the second label of the device.